Last reviewed · How we verify
IPN01195
At a glance
| Generic name | IPN01195 |
|---|---|
| Sponsor | Ipsen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPN01195 CI brief — competitive landscape report
- IPN01195 updates RSS · CI watch RSS
- Ipsen portfolio CI